Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2296 to 2310 of 8976 results

  1. Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]

    Awaiting development Reference number: GID-TA11828 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

    In development Reference number: GID-TA10089 Expected publication date:  15 November 2017

    Technology appraisal guidance
    In development

  3. Digital technologies to support monitoring of vision change at home for people with age-related macular degeneration: early use assessment

    In development Reference number: GID-HTE10073 Expected publication date:  15 September 2026

    Health technology evaluations
    In development

  4. Dostarlimab for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660]

    Awaiting development Reference number: GID-TA11870 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]

    Awaiting development Reference number: GID-TA11473 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]

    Awaiting development Reference number: GID-TA11308 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years [ID3897]

    Awaiting development Reference number: GID-TA11437 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Eneboparatide for treating chronic hypoparathyroidism [ID6532]

    Awaiting development Reference number: GID-TA11688 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

    Awaiting development Reference number: GID-TA11094 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]

    Awaiting development Reference number: GID-TA11425 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Capsule sponge tests for detection of Barrett's oesophagus and early-stage oesophageal cancer and surveillance of Barrett's oesophagus [ID6683]

    In development Reference number: GID-TA11960 Expected publication date:  24 February 2027

    Technology appraisal guidance
    In development

  12. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]

    Awaiting development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date:  15 October 2026

    Interventional procedures guidance
    In development

  14. Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]

    In development Reference number: GID-TA11780 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]

    Awaiting development Reference number: GID-TA11661 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development